跳至主要内容
临床试验/NCT01578135
NCT01578135已完成不适用

French National Longitudinal Prospective Follow-up of Children Born Small for Gestational Age and Treated With Norditropin SimpleXx (French Health Authorities Commitment)

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 291 人开始时间: 2007年3月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
291
试验地点
1
主要终点
Growth in height

研究概览

简要总结

This study is conducted in Europe. The aim of the study is to describe the patient population and therapeutic practices (study phase I), assess efficacy on growth and adult height and assess tolerance of somatropin (Norditropin® SimpleXx®) (study phase II)

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Born small for gestational age

排除标准

  • 未提供

研究组 & 干预措施

Phase I

干预措施: somatropin (Drug)

Phase II

干预措施: somatropin (Drug)

结局指标

主要结局

Growth in height

时间窗: 6 months after inclusion into registry and then annually until adult height is reached

次要结局

  • Insulin-Like Growth Factor 1 (IGF-1)(6 months after inclusion into registry and then annually until adult height is reached)
  • Blood pressure: Systolic and diastolic(6 months after inclusion into registry and then annually until adult height is reached)
  • Bone age(6 months after inclusion into registry and then annually until adult height is reached)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

French National Registry of Children Born Small for... | 临床试验